Ann Gils

Biochemistry, Genetics and Molecular Biology · Life Sciences

58h-index11.3kcitations331works9.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Inflammatory Bowel Disease(111), Blood Coagulation and Thrombosis Mechanisms(80), Microscopic Colitis(69), Protease and Inhibitor Mechanisms(67), Immunodeficiency and Autoimmune Disorders(55)

Publications328 total

The association of post-stroke fatigue with life balance, participation and quality of life one year post-stroke.
Lirias (KU Leuven)·2024
Next generation point-of-care test for therapeutic drug monitoring of adalimumab in patients diagnosed with autoimmune diseases
Biosensors and Bioelectronics·2022· 33 citedOpen Access
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab
Inflammatory Bowel Diseases·2022· 27 cited
Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy
The Journal of Pediatrics·2021· 18 citedOpen Access
P311 Intensive dried blood spot sampling shows a higher drug exposure throughout the first 24 weeks of therapy in ustekinumab-treated Crohn’s disease patients achieving endoscopic remission
Journal of Crohn s and Colitis·2021
The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases
British Journal of Clinical Pharmacology·2021· 13 citedOpen Access
Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response
GastroHep·2021· 17 citedOpen Access
Author response for "Effect of vedolizumab dose intensification on serum drug concentrations and regain of response in inflammatory bowel disease patients with secondary loss of response"
2021Open Access
Tissue Exposure does not Explain Non-Response in Ulcerative Colitis Patients with Adequate Serum Vedolizumab Concentrations
Journal of Crohn s and Colitis·2020· 15 citedOpen Access
インフリキシマブの先行品からバイオシミラーCT-P13への切り替え後の有効性,安全性,および薬物動態の評価 : 大規模三次医療施設の経験
Medical Entomology and Zoology·2020Open Access
Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label
European Journal of Gastroenterology & Hepatology·2020· 11 cited
Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis
Journal of Pharmaceutical and Biomedical Analysis·2020· 4 citedOpen Access
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease
British Journal of Clinical Pharmacology·2020· 29 citedOpen Access
Evaluating an easy sampling method using dried blood spots to determine vedolizumab concentrations
Journal of Pharmaceutical and Biomedical Analysis·2020· 19 citedOpen Access
P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease
Journal of Crohn s and Colitis·2020· 3 citedOpen Access
DOP14 Modelling of the relationship between infliximab exposure, faecal calprotectin, and endoscopic remission in patients with Crohn’s disease
Journal of Crohn s and Colitis·2020· 3 citedOpen Access
Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease Patients
Journal of Clinical Gastroenterology·2019· 19 cited
Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center
Inflammatory Bowel Diseases·2019· 14 cited
A SIMPLE point-of-care test for drug monitoring in whole blood of patients with autoimmune diseases
Lirias (KU Leuven)·2019Open Access
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients
Journal of Crohn s and Colitis·2019· 38 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

Séverine Vermeire(28), Niels Vande Casteele(19), Marc Ferrante(17), Gert Van Assche(15), Paul Declerck(14), Paul Rutgeerts(11), Filip Baert(7), Thomas Van Stappen(7), Griet Compernolle(6), Sharat Singh(6), Maja Noman(6), Scott Hauenstein(5), Konstantinos Papamichael(5), Thomas Billiet(5), Bram Verstockt(5), Peter Bossuyt(4), Peter Carmeliet(4), Sophie Tops(4), Erwin Dreesen(4), Vera Ballet(3)